ESMO Breast Cancer is an annual congress taking place for the first time on 2-4 May 2019 in Berlin, Germany. Brought to you by ESMO, your trusted provider of specialised education in oncology.
We are proud to present our research at ESMO Congress 2022 in Paris.
Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
Bitte beachten Sie unsere neue Anschrift ab dem 18. Juli 2022.
In a paper in "The Breast" we discuss the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials.
GBG Forschungs GmbHDornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440
+49 6102 7480-0 | nfGBGd